<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Sedentary lifestyle and a western diet promote <z:hpo ids='HP_0011011'>subacute</z:hpo>-<z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, and subsequently dysglycemia </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the current study was to evaluate the efficacy of the <z:chebi fb="0" ids="35472">anti-inflammatory drug</z:chebi> salsalate to improve glycemia by reducing systemic <z:mp ids='MP_0001845'>inflammation</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> adults at risk for the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In a double-masked, placebo controlled trial, we evaluated 20 <z:mp ids='MP_0001261'>obese</z:mp> nondiabetic adults at baseline and after 1 month of salsalate or placebo </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Compared with placebo, salsalate reduced fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> 13% (P &lt; 0.002), glycemic response after an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> challenge 20% (P &lt; 0.004), and glycated albumin 17% (P &lt; 0.0003) </plain></SENT>
<SENT sid="4" pm="."><plain>Although insulin levels were unchanged, fasting and oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels decreased in the salsalate-treated subjects compared with placebo (P &lt; 0.03), consistent with improved insulin sensitivity and a known effect of <z:chebi fb="1" ids="30762">salicylates</z:chebi> to inhibit insulin clearance </plain></SENT>
<SENT sid="5" pm="."><plain>Adiponectin increased 57% after salsalate compared with placebo (P &lt; 0.003) </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, within the group of salsalate-treated subjects, circulating levels of C-reactive protein were reduced by 34% (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: This proof-of-principle study demonstrates that salsalate reduces glycemia and may improve inflammatory cardiovascular risk indexes in overweight individuals </plain></SENT>
<SENT sid="8" pm="."><plain>These data support the hypothesis that <z:hpo ids='HP_0011011'>subacute</z:hpo>-<z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> contributes to the pathogenesis of <z:hpo ids='HP_0001513'>obesity</z:hpo>-related dysglycemia and that targeting <z:mp ids='MP_0001845'>inflammation</z:mp> may provide a therapeutic route for <z:mp ids='MP_0002055'>diabetes</z:mp> prevention </plain></SENT>
</text></document>